Although the scientific community had already identified differences in the effects of chemotherapy between men and women, their researchers say this is the first study to extend the analysis to other treatments.
An American study published in the Journal Of Clinical Oncology shows that women are 34% more likely than men to suffer adverse events (AEs) after cancer treatment. The data are the result of research analyzing treatment-emergent adverse events by gender in Phase II and III clinical trials conducted between 1980 and 2019 by the South Western Oncology Group (SWOG), one of five group cooperatives that make up the National Network of form, clinical trials were conducted by the National Cancer Institute of the United States. Sex-specific cancers were excluded from the analysis.
A total of 23,296 patients were analyzed, 8,838 women (37.9% of the total) and 14,458 men (62.1%) from 202 studies that reported more than 270,000 adverse events. Overall, 64.6% of all patients experienced one or more serious side effects. The most common cancers in this group studied were gastrointestinal (26.1%), lung (20.5%) and leukemia (12.1%). Overall, 34.7% of patients were 65 years or older. In terms of treatments used, chemotherapy was particularly common (68.4%) in the 1989-1999 studies, while immunotherapy (53.6%) and targeted therapies (50.3%) were more common from 2010-2019.
Receive notifications from Google News